BRISBANE, Calif., June 30, 2025 -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company, has announced that they have received regulatory clearance from the National Medical Products Administration (NMPA) in China to proceed with a pivotal trial for their drug amezalpat (TPST-1120). This trial will assess the efficacy of amezalpat in combination with atezolizumab and bevacizumab, the current standard of care, in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma $(HCC)$. This approval marks an important step for Tempest Therapeutics as they aim to reach global markets, particularly in China, which has the highest population of HCC patients. The clearance follows prior approvals from the FDA and EMA, highlighting the drug's potential impact on patient care.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.